DMT310-005 Topical in the Treatment of Acne Rosacea

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Acne Rosacea

In brief

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne rosacea.

Key facts

Study ID

NCT05108025

Run by

Dermata Therapeutics

People needed

180

Starts

2021-11-15

Expected to finish

2022-12-01

Last updated by the study team

2022-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is male or non-pregnant female at least 18 years of age.
• Clinical diagnosis of moderate to severe papulopustular acne rosacea as determined by:
• Investigator's Global Assessment (IGA) at Randomization score of 3 or 4. Patient has at least 15 inflammatory lesions on the face
• Patient is willing to apply the Investigational Product as directed
• Patient is willing and able to comply with the protocol

You may not qualify if…

• Patient is pregnant or planning to become pregnant Patient is taking a topical therapy on the face which may affect the patient's rosacea

Where it is running

• Dermata Investigational Site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.